WATCH: Get an overview of BiomeBank with this short Investor Presentation by CEO and Co-founder Dr Sam Costello (2min)
Investing in
BiomeBank
BiomeBank is well-positioned to become a global leader in the discovery and commercialisation of microbial therapies. Our current donor-derived therapy is the world’s first approved biotherapeutic for the treatment of recurrent and refractory clostridioides difficile infection, a significant milestone in the microbiome field.
BiomeBank’s multi-disciplinary team of microbiome experts has now successfully developed a breakthrough co-culturing platform, ConsortiomeTM that allows us to produce a range of complex synthetic bacterial communities that can replicate the current donor-derived microbial therapies. However, because these new co-cultured therapies are produced in a bioreactor, they can be manufactured at a much lower cost and more easily scaled than donor-derived treatments.
More importantly, this new generation of therapies has the potential to be enriched for defined and patented disease-specific functions and used to treat the unmet medical needs of patients globally.
A unique ecosystem based approach to drug development
Like many thriving ecosystems found in nature, diversity is the key ingredient for a healthy gut microbiota. Modern lifestyles and environments are causing gut bacterial diversity to decline, and this is associated with the rise of numerous chronic diseases.
BiomeBank is at the forefront of developing therapies that harness the power of ecology and technology to engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties that manifest at the community level.
ConsortiomeTM:
Our Breakthrough Technology
Our team of translational microbiome experts have developed a breakthrough co-culturing platform that has enabled us to generate an artificial human gut microbial community in a bioreactor – the Consortiome™.
Consortiome™ is a rationally designed consortia containing more than 90% of the known gene families in a healthy person’s microbiome
The Consortiome™ platform enables the development of bespoke therapies with targeted functions to treat disease at a much lower cost than other microbial products.
OVERLAP OF GENE FAMILIES
BETWEEN HEALTHY DONORS
& BIOMEBANK’S CONSORTIOME™
Annotation using the NCBI COG database (”Clusters of Orthologous Genes”) identified members of 1775 gene families from a healthy donor metagenome, of which over 90% of gene families were represented in the consortium metagenome.
WATCH: CEO and Co-founder Dr Sam Costello explain BiomeBank’s
revolutionary ConsortiomeTM Technology in more detail (2min)
The Market for Microbial Therapies
The global microbial therapeutic market is projected to reach a valuation of US$30 billion by 2030, making the gut microbiome a new frontier in medicine.
BiomeBank’s breakthrough co-culturing technology mean it is well-positioned to become a global leader in the sector. Our first such co-cultured therapy, BB265 for Ulcerative Colitis, has been designed using data from use of BiomeBank’s donor derived therapy in clinical trials and will enter human trials in 2024.
10% market penetration = $1.3 billion per year
Ulcerative Colitis
Current therapies are inadequate with 30-35% remission rates and a 10-40% loss of response in patients. Also, many existing therapies for UC have risks of adverse events related to immune suppression, resulting in a large unmet medical need. 2
BiomeBank’s BB265 is formulated to disrupt the UC market and to provide a better solution patients with ulcerative colitis.
1. Global data UC report 2023;
2 Savelkoul et al Inflamm bowel dis 2022
different?
The Development Pipeline
BiomeBank is now leveraging the real-world, human data collected from these therapies as well as employing our cutting-edge ConsortiomeTM platform to engineer and test a pipeline of novel, co-cultured microbial therapies.
The Potential Drug Candidates
• BB265
BB265 is a rationally designed cultured microbiome therapy engineered for the treatment of ulcerative colitis. BB265 was developed using BiomeBank’s Consortiome platform and data from a discovery trial using BiomictraTM (donor derived) therapy in patients with active ulcerative colitis. BB265 is scheduled to enter a phase 1b/2a study in 2025.
• BB128
BB128 is a rationally designed cultured microbiome therapy engineered for the treatment of an orphan disease indication. A discovery trial in this orphan disease indication is underway using BiomictraTM.
Optimising the
Drug Discovery
Funnel
1.
Leveraging real-world, human data from our existing therapies to establish the causation of disease, our ‘human-first’ model of discovery allows us to more rapidly and precisely identify the ‘mechanism of action’ when compared to animal models.
2.
DEVELOP
Harnessing the latest technology, we mine the real-world data and select candidate strains from our leading culture collection. Employing our cutting-edge ConsortiomeTM platform we engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties that manifest at the community level.
3.
OPTIMISE
Delivering BiomeBank potential drug candidates with the highest chance of clinical success.